UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the 

Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): January 30, 2015 

ABBVIE INC. 

(Exact name of registrant as specified in its charter) 

 [DATA_TABLE_REMOVED]  

1 North Waukegan Road 

North Chicago, Illinois 60064-6400 

(Address of principal executive offices)(Zip Code) 

Registrantâ€™s telephone number, including area code:  (847) 932-7900 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Item 2.02. Results of Operations and Financial Condition 

On January 30, 2015, AbbVie Inc. issued a press release announcing its results of operations for the fourth quarter and full year 2014. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. 

Item 9.01 Financial Statements and Exhibits 

  Exhibit No.       Exhibit   

  99.1       Press Release dated January 30, 2015 (furnished pursuant to Item 2.02).    

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

EXHIBIT INDEX 

  Exhibit 

 No.       Exhibit   

  99.1       Press Release dated January 30, 2015 (furnished pursuant to Item 2.02).